Yuka Shimizu, Ph.D.

Yuka Shimizu, Ph.D. has a diverse and extensive work experience in the field of cell therapy and molecular biology. Yuka currently serves as the Head of Process Development - Cell Therapy at Orbsen Therapeutics Limited since June 2019. Prior to this, they worked as a Research Scientist in cell therapy at the same company starting from November 2017.

Before joining Orbsen Therapeutics Limited, Dr. Shimizu had a significant role at NHS Blood and Transplant from April 2015 to December 2017. Yuka served as a Cell and Molecular Therapy Specialist, focusing on stem cell and immunotherapy. Yuka'sresponsibilities involved research and technical development in the process development and implementation of novel Mesenchymal Stem Cell (MSC) therapy products for clinical trials, as well as the establishment of cell isolation and selection/enrichment protocols.

In their earlier career, they worked as a Principal Research Specialist at The University of Arizona from September 2013 to December 2014. Here, they managed and supervised subordinate staff, conducted research activities, and received recognition for technical expertise and improvement in gene expression methods.

Dr. Shimizu also gained valuable experience as a Ph.D. Candidate/Graduate Research Assistant at the University of Illinois at Chicago from 2008 to 2013. Yuka'sresearch focused on investigating the role of growth factors in lung inflammatory diseases, specifically in understanding the molecular mechanisms of nmMLCK gene expression in asthma patients.

Furthermore, they worked as a Research Associate at the University of California, Davis from August 2006 to July 2008. Here, they carried out molecular biology experiments and research, particularly in characterization of the zinc finger protein as a gene therapy tool, while also providing mentoring and supervision to team members.

Dr. Shimizu began their professional journey as a Molecular Biology Intern at Pioneer Hi-Bred International Inc in June 2005, gaining early experience in the field.

Overall, Dr. Yuka Shimizu's work experience demonstrates their expertise and contributions to various aspects of cell therapy, molecular biology, and research management.

Yuka Shimizu, Ph.D. received their B.S. in Biochemistry and Molecular Biology from the University of California, Davis in 2006. Afterward, they pursued their education at the University of Illinois Chicago, where they completed their Doctor of Philosophy (Ph.D.) in Biochemistry and Molecular Genetics from 2008 to 2014.